Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer

Conditions

metastatic colorectal cancer

Yu Sunakawa, Sebastian Stintzing, Shu Cao, John Luecke, Debrah M. Thompson et al. (20 authors)

Annals of Oncology2018-10-01

Association of immune-related genes to neutrophil-lymphocyte ratio (NLR) with survival of cetuximab treatment for metastatic colorectal cancer (mCRC): JACCRO CC-05/06AR.

Yu Sunakawa, Dongyun Yang, Bonnie LaFleur, John Luecke, Debrah M. Thompson et al. (20 authors)

Journal of Clinical Oncology2017-05-201 citations

10.1200/jco.2017.35.15_suppl.11613

Alteration of ADCC-related genes as a novel predictor of efficacy of cetuximab (cet)-based chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC) (JACCRO CC-05/06 AR).

Yu Sunakawa, Dongyun Yang, Shu Cao, Chris Roberts, Eva Wang et al. (20 authors)

Journal of Clinical Oncology2016-02-01

10.1200/jco.2016.34.4_suppl.589

Association of EGFR CA simple sequence repeat 1 (CA-SSR1) variant with cetuximab (cet)-induced skin toxicity (ST) in Japanese metastatic colorectal cancer (mCRC) patients (pts) with overexpressed EGFR and KRAS exon 2 wild-type (KRAS wt) (JACCRO CC-05/06 AR).

Wataru Ichikawa, Yu Sunakawa, Akihito Tsuji, Takehiro Takahashi, Tadamichi Denda et al. (20 authors)

Journal of Clinical Oncology2015-01-20

10.1200/jco.2015.33.3_suppl.582

EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese (JPN) patients (pts) with metastatic colorectal cancer (mCRC) harboring overexpressed EGFR and KRAS exon 2 wild-type (KRAS wt) treated with cetuximab (cet) plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR).

Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji, Miriana Moran, Stephanie H. Astrow et al. (18 authors)

Journal of Clinical Oncology2015-01-20

10.1200/jco.2015.33.3_suppl.618

Interventions

cetuximab loading dose 400mg/m2, 250mg/m2/week L-OHP 85mg/m2/biweekly levofololinate 200mg/m2/biweekly 5-FU bolus 400 mg/m2/biweekly 5-FU continuous 2,400 mgm2/biweekly / cetuximab loding dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who are registered in JACCRO CC-05 study (UMIN000004197) or in JACCRO CC-06 study (UMIN000007022) and started protocol therapy (2) Remaining the paraffin-embedded section of tumor tissue (3) Approved to supply the section for this research by IRB (4) Getting the informed consent from the patient, in the case of death or disappearance, approval of IRB and the representative of hospital must be taken

Exclusion criteria

Exclusion criteria: (1) Patients who are regarded as inadequate for study enrollment by investigators (2) Patients who refuse to supply the section

Design outcomes

Primary

Measure	Time frame
Correlation between the reported biomarkers (EGFR expression, ligand expression to EGFR, BRAF, PI3K, and PTEN expression) or new ones (DNA microarray, analysis of microRNA expression, and DNA SNP analysis) and the response to cetuximab containing combination therapies	—

Countries

Japan

Contacts

Public ContactMasashi Fujii

Japan Clinical Cancer Research Organization Office

jaccro@jaccro.or.jp03-5579-9893

Outcome results

None listed